Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reward processing in children with affective dysregulation.

JCPP advances·2026
Same author

Assessing Camouflaging in Adolescence: Psychometric Evaluation of the German Camouflaging Autistic Traits Questionnaire (CAT-Q/DE).

Journal of autism and developmental disorders·2026
Same author

Ten years of a gender identity service for children and adolescents in Germany: demographic and clinical patterns.

European child & adolescent psychiatry·2026
Same author

[Profiling involuntarily hospitalized patients according to risk to themselves and/or risk to others].

Fortschritte der Neurologie-Psychiatrie·2026
Same author

Adaptive stepped care in preschool-age children with ADHD symptoms: a multicentre study including two consecutive randomised controlled trials (ESCApreschool).

European child & adolescent psychiatry·2026
Same author

Model-based analysis of stop-signal data reveals robust neural and clinical correlates of evidence accumulation but not inhibition.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026

Related Experiment Video

Updated: Jun 12, 2026

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex
04:44

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex

Published on: February 16, 2024

Augmentation with pregabalin in schizophrenia.

Susanne Englisch1, Andrea Esser, Frank Enning

  • 1Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany.

Journal of Clinical Psychopharmacology
|June 10, 2010
PubMed
Summary
This summary is machine-generated.

Pregabalin effectively reduced treatment-resistant anxiety in schizophrenia patients. This augmentation strategy improved anxiety, psychosis, and mood symptoms without adverse events, suggesting a tolerable new treatment option.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Related Experiment Videos

Last Updated: Jun 12, 2026

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex
04:44

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex

Published on: February 16, 2024

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Anxiety is a primary symptom in schizophrenia, worsening patient burden and treatment resistance.
  • Potential causes include residual delusions, negative symptoms, depression, panic attacks, social phobia, and benzodiazepine withdrawal.
  • Pregabalin, targeting alpha2delta subunits of voltage-gated calcium channels, modulates neurotransmitters and has shown efficacy in anxiety for other disorders.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of pregabalin as an augmentation strategy for treatment-resistant anxiety in schizophrenia patients.
  • To assess the impact of pregabalin on anxiety, psychotic symptoms, mood, and medication requirements.

Main Methods:

  • A case series of 11 schizophrenia patients with treatment-resistant anxiety was analyzed.
  • Patients received augmentation therapy with pregabalin.
  • Anxiety, positive and negative psychotic symptoms, and depression were assessed using standardized scales (Hamilton Anxiety Scale, PANSS, SANS, Calgary Depression Scale for Schizophrenia).

Main Results:

  • Pregabalin augmentation significantly reduced Hamilton Anxiety Scale scores.
  • Improvements were observed in positive and negative psychotic symptoms and mood.
  • Complete discontinuation of benzodiazepines and a reduction in antipsychotic dosage were achieved in some patients.
  • No pharmacokinetic interactions or adverse events were reported.

Conclusions:

  • Pregabalin appears to be an effective and well-tolerated augmentation strategy for managing anxiety syndromes in schizophrenia.
  • Further research is warranted to explore pregabalin's benefits across different anxiety subsyndromes in schizophrenia and compare it to placebo and active treatments.